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DNA vaccination with the M3 gene, encoding an immune evasion molecule expressed during both the acute
lytic and persistent phases of murid gammaherpesvirus 68 infection, yielded a significantly lower titer of virus
in the lung than controls. The protection seen was dependent on T cells, and we mapped an epitope recognized
by CD8 T cells. The immune response to this epitope follows the same kinetics as lytic cycle antigens, despite
the fact that this gene is expressed in both lytic and persistent stages of infection. This has important
implications for our understanding of T-cell responses to putative latency-associated gammaherpesvirus
proteins and how vaccination may improve control of these viruses.
Members of the gammaherpesvirus subfamily are important
human pathogens and are associated with significant diseases,
such as infectious mononucleosis, nasopharyngeal carcinoma,
and lymphoid malignancies. The isolation of a gammaherpes-
virus that infects mice, murid gammaherpesvirus 68 (MHV-68,
HV-68; International Committee on Taxonomy of Viruses
name, murid herpesvirus 4), provides an experimental model
for the study of disease caused by human and animal gamma-
herpesviruses (3, 12, 16, 29). This virus is related to the human
viruses Epstein-Barr virus and Kaposi’s sarcoma-associated
herpesvirus (human herpesvirus 8) as well as animal viruses,
such as ovine herpesvirus 2 and herpesvirus saimiri. As such, it
is a useful model with which to test hypotheses concerning the
immunological control of these viruses. Most vaccination strat-
egies have concentrated on structural proteins or those anti-
gens expressed during lytic replication (8, 11, 19, 30), but less
is known about the efficacy of targeting latency-associated an-
tigens. In the MHV-68 system, we and others have shown that
vaccination with certain lytic-phase antigens induces protec-
tion from virus replication in the lungs and reduces the initial
level of latently infected cells (9, 17). In contrast, vaccination
with a latency-specific protein, M2, greatly reduced the initial
level of latently infected cells but had no effect on lytic repli-
cation in the lungs (24, 25). Neither vaccination strategy re-
duced the level of latent virus in the mice long term. However,
protection from the establishment of long-term latency by vac-
cination is theoretically possible, since infection with MHV-68
mutants which are unable to reactivate from or establish la-
tency prevents residual latency after challenge with wild-type
virus (4, 21). Little is known concerning the effect of priming
T-cell responses that target both lytic and persistent phases of
the virus life cycle. In this regard, the M3 protein of MHV-68
is an attractive target, since it is expressed during lytic virus
replication as well as during persistence and is a candidate
latency-associated antigen (14, 24, 26, 28). Unlike M2, which is
expressed for only a few days around 14 days postinfection,
mRNA for M3 is detectable for at least 1 month postinfection
and probably much longer (24). What makes this protein of
particular interest is its function as an immune evasion protein.
The M3 protein can block the function of CC and CXC che-
mokines and may block sufficient CD8-T-cell recruitment into
the site of infection and/or lymphoid tissues (1, 7, 27). In this
study we wished to determine whether the M3 protein elicited
an antiviral T-cell response and test its effect on the control of
different stages of the infection.
We vaccinated mice by using a technique that we have used
successfully before, specifically, DNA vaccination with a gene
gun, using protocols similar to those described previously (25).
The complete M3 open reading frame with three copies of an
influenza hemagglutinin epitope tag sequence at the 3 end was





der conditions described previously (10). The amplified prod-
uct was cut with the restriction enzymes NotI and BamHI and
inserted by molecular cloning between the NotI and BamHI
sites of the DNA vaccine vector pVR1255 (5) to generate
pVR1255/M3. Expression of M3 protein by this vector was
confirmed by calcium phosphate-mediated transfection into
HEK293T cells and detection of [35S]Met-labeled M3 protein
in the supernatant by sodium dodecyl sulfate-polyacrylamide
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gel electrophoresis and autoradiography as described previ-
ously (data not shown) (20). A pVR155 construct containing
the luciferase (Luc) gene was used as a negative control.
BALB/c mice were immunized three times at 2-week intervals
with 0.6 to 1.8 g of DNA by gene gun and then challenged
with 400 PFU of MHV-68 by the intranasal (i.n.) route 2 to 3
weeks after the last boost. Lungs were removed 7 days after
infection to assess the degree of protection from acute infec-
tion (Fig. 1). Mice vaccinated with pVR1255/M3 had a signif-
icantly lower titer of virus in the lungs than those vaccinated
with pVR1255/Luc. The titers in both groups continued to
decline at day 10 postinfection (data not shown), indicating
there was not just a delay in viral replication in the M3-vacci-
nated group. To measure whether this protection extended to
the persistent/latent phase of the infection, we infected vacci-
nated mice with MHV-68 and then removed the spleens at 14
days postinfection. The latent virus burden at this time point
was measured using quantitative fluorescent PCR, as previ-
ously described (25). We observed a variable decrease in virus
burden between M3-vaccinated and vector-alone-vaccinated
groups, which was statistically significant for some experiments
but not others (data not shown). We did not observe any
difference in the latent virus burden between the two groups at
28 days postinfection. At both 14 and 28 days postinfection, we
detected no free virus in the spleen. Therefore, we concluded
that DNA vaccination with M3 conferred partial protection
from the acute phase of infection in the lungs but did not have
a reproducible effect on the persistent/latent stages of the
infection. The lack of effect on latent infection may imply
either that M3 is expressed only in a subset of latently infected
cells or that it is expressed only during the lytic cycle and not
in latency at all. In either case, this would not render the
majority of latently infected cells susceptible to immune rec-
ognition. In support of the latter hypothesis, we have previ-
ously shown, using a latently infected B-cell line (S11), that
unlike M2, M3 was not expressed in latently infected cells (6).
Currently, little is known concerning heterogeneity in gene
expression during MHV-68 latency; however, other gamma-
herpesviruses have several different latent programs of gene
expression (15). It is also possible that a vaccination regime
that induces a stronger T immune response against M3 will
reduce the titer of latent virus to a larger extent than was seen
with DNA vaccination.
Previous studies have reported a critical role for T cells in
the control of MHV-68 infection (2, 18, 22), so we wished to
test whether the protection we observed was due to T cells. To
test this, we vaccinated mice as described above, and then 2 to
3 weeks after the last boost we depleted T-cell subsets prior to
infection. One group was depleted of CD4 T cells by intraperi-
toneal injection of anti-CD4 antibody (GK1.5; 300 g on days
1, 1, and 4 relative to infection), another group received
anti-CD8 antibody (TIB210), and control groups received the
same dose of rat immunoglobulin G. Mice were then infected
with 400 PFU of MHV-68 i.n., and 7 days later, the lungs were
removed for virus titration. The protection afforded by M3
vaccination was eliminated by depletion of either CD8 (Fig.
2A) or CD4 T cells (Fig. 2B). This demonstrated that vacci-
FIG. 1. DNA vaccination with M3 induces protection from acute
MHV-68 infection in the lung. BALB/c mice were DNA vaccinated,
using a gene gun, three times with pVR1255 encoding either the M3
gene (closed circles) or luciferase (luc) as a negative control (open
circles). Two to three weeks after the final immunization, mice were
infected i.n. with 400 PFU of MHV-68, and then the lungs were
removed 7 days later and the titer of virus was measured by plaque
assay. Each data point represents the titer from an individual mouse.
P values were calculated using Student’s t test. The data are represen-
tative of four experiments.
FIG. 2. Protection is eliminated by T-cell depletion. BALB/c mice
were DNA vaccinated with either pVR1255/M3 or pVR1255/Luc as
described, and then groups were treated with either anti-CD8 (A) or
anti-CD4 (B) antibody to deplete T-cell subsets, and the other groups
were treated with rat immunoglobulin G (IgG) as a control. Depletion
was initiated just prior to infection with MHV-68 i.n., and lungs were
removed 7 days later. Titers of virus in the lungs are shown. Each point
represents an individual mouse. P values were calculated using Stu-
dent’s t test. Data are representative of two experiments.
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nation with M3 induced a T-cell response that mediated the
observed protection. It also ruled out the possibility that anti-
bodies against the M3 protein were blocking its immune eva-
sion function and attenuating the infection. In addition, it
shows that synthesis of the M3 protein itself, a secreted protein
shown to bind chemokines (14, 26, 28), was not directly medi-
ating protection from infection.
To determine the fine specificity of the T-cell response in-
duced against the M3 protein, we synthesized overlapping 15-
mer peptides covering the complete sequence of the protein
(overlapping by 10 amino acids). We then used a previously
described gamma interferon (IFN-) enzyme-linked immuno-
spot (ELISPOT) assay (23) to screen which peptides elicited a
response from either CD8 or CD4 T cells. Spleen cells from
mice vaccinated with M3 and infected for 7 days as described
were the responder population in this assay. We resynthesized
the peptides that scored positive in the screen and mapped an
epitope, M3150-158 (AYVELQTEL), that consistently elicited
IFN- secretion from CD8 T cells. This peptide conforms to
the Kd consensus binding motif (x[Y/]xxxxxx[I/L/V]) and also
binds to the Kd molecule, as determined by using an RMA-S
stabilization assay (data not shown). We did not identify any
additional peptides that elicited responses from purified CD4
T cells. We used this information to measure how much our
DNA vaccination regime enhanced the response to M3 relative
to that with mock-vaccinated mice. After vaccination and ex-
posure to virus for 7 days, M3-vaccinated mice had 185  28
spot-forming cells/106 spleen cells compared with 14  10
spot-forming cells/106 spleen cells in Luc-vaccinated controls.
Therefore, vaccination with M3 enhanced the CD8-T-cell re-
sponse to this epitope by approximately 13-fold. Given that we
could not detect a CD4 epitope within the M3 protein, it was
unexpected that CD4 depletion abrogated protection elicited
by DNA vaccination (Fig. 2). It has been shown that CD4 T
cells play a role in the clearance of the acute infection (18), and
perhaps with the enhanced virus replication observed after
CD4 depletion the protective effect of vaccination is masked.
Alternatively, it is formally possible that there are CD4-T-cell
epitopes within M3 that were not detected using our screening
regime.
We wished to test whether the CD8-T-cell epitope we iden-
tified was recognized in the context of infection without vacci-
nation and to establish the kinetics of this response. Therefore,
we infected BALB/c mice with MHV-68, and at various times
postinfection we removed the spleens and bronchoalveolar
lavage (BAL) and used an IFN- ELISPOT assay to measure
the frequency of cells responding to this epitope. For purposes
of comparison, we included a known lytic cycle epitope
(ORF65131-140) (23) and a known latent cycle epitope
(M291-99) (6, 24). As can be seen in Fig. 3, the response to the
M3 epitope was maximal in the BAL at 11 days postinfection
and subsequently declined. In the spleen, the response was
elevated between 11 and 14 days postinfection before declining
to a steady level that was maintained until the end of the
experiment. Reponses in the draining mediastinal lymph node
were similar to those in the spleen (data not shown). Overall,
the kinetics were strikingly similar to those for the lytic cycle
ORF65131-140 epitope. As previously reported, the response to
the M291-99 epitope was induced with slower kinetics (13) and
was more pronounced in lymphoid tissue than in the lungs. The
induction of the M3-specific T-cell response with lytic cycle
kinetics is not surprising, since it is made during acute viral
replication in the lungs (24). However, it was unexpected that
the response declined with the same kinetics as for lytic cycle
antigens, since M3 is expressed for several weeks after the
establishment of viral latency. The studies showing prolonged
M3 expression measured mRNA levels, so it is possible that
the amount of M3 protein produced in latency is much lower
than during lytic replication, which may provide less stimulus
to maintain the M3-specific T-cell response.
In conclusion, we show that T cells recognizing the M3
protein of MHV-68 can afford partial protection from the
acute phase of infection, but protection from the early latent
phase of infection was not observed with consistency. This
illustrates that a viral protein whose primary function is im-
mune evasion can also be the target for antiviral T-cell attack.
The response to a CD8-T-cell epitope in this protein is induced
with kinetics similar to those for lytic cycle antigens during
infection with MHV-68. This work furthers our understanding
of the immune response to gammaherpesvirus proteins ex-
FIG. 3. Kinetics of the response to the CD8-T-cell epitope in M3.
BALB/c mice were infected with 400 PFU of MHV-68 i.n., and then at
the times shown, BAL and spleens were removed and cells were used in
an IFN- ELISPOT assay. We measured the frequency of cells respond-
ing to the following peptides: M3150-158 (squares), ORF65131-140 (trian-
gles), and M291-99 (diamonds). Data are representative of two experi-
ments; error bars show one standard deviation. BAL was pooled from
groups of six mice, whereas spleens were measured individually (n  4 to
6).
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pressed during latency and may lead to better strategies to
contain these important pathogens.
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